Data / Form D filings / Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc.: Form D filings
Rubius Therapeutics, Inc., a biotechnology company in Cambridge, MA, filed 2 Form D notices with the SEC between 2017 and 2018. The latest, on March 1, 2018, reports $101.2 million sold of a $101.2 million offering to 27 investors.
Find out what Rubius Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 325 VASSAR STREET, SUITE 1A, Cambridge, MA, 02139
- Phone
- (617) 679-9600
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2013
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1709401
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 1, 2018 | New notice | $101,200,005 | $101,200,005 | $0 | 27 | Feb 23, 2018 | sec.gov |
| Jun 22, 2017 | New notice | $120,000,064 | $115,000,060 | $5,000,004 | 16 | Jun 7, 2017 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Christopher L. Carpenter | Executive Officer | |
| Torben Straight Nissen | Executive Officer, Director | |
| Robert S. Langer | Director | |
| Noubar B. Afeyan | Director | |
| Francis B. Cuss | Director | |
| Catherine B. Sohn | Director | |
| Michael S. Rosenblatt | Director | |
| Roger S. Pomerantz | Director | |
| Joanne Protano | Executive Officer | |
| David Straight Epstein | Director | |
| Andrew B. Oh | Executive Officer |
Other biotechnology companies in Massachusetts that filed recently
- Zai Lab Ltd $249.9 million · Nov 9, 2026
- AI3 Bio, Inc. offering · Nov 4, 2026
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
- Axelyf, Inc. $2.6 million · Oct 13, 2026
- BIOVENTRIX, INC. $1.2 million · Oct 8, 2026
- Opus KSD, Inc. $680,801 · Oct 1, 2026
- Xact Bio, Inc. $10 million · Sep 28, 2026
- Way Biosolutions, Inc. $2 million · Sep 25, 2026
- AutoIVF, Inc. $1.5 million · Sep 25, 2026
- Typewriter Therapeutics, Inc. $56.3 million · Sep 21, 2026
Every Form D from the week of Feb 26, 2018 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Rubius Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.